Pegfilgrastim (Neulasta®) for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000438
English
Authors' recommendations:
Pegfilgrastim (Neulasta®) is recommended as an option for restricted use within NHS Wales for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
Its use should be restricted to patients where the risk of febrile neutropenia is high and where the risk of neutropenia from chemotherapy is likely to be prolonged (more than six days) or for patients with special circumstances e.g. geographical access, needle phobia.
Pegfilgrastim (Neulasta®) is not suitable for shared care within NHS Wales.
Details
Project Status:
Completed
Year Published:
2008
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=104699&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Neutropenia
- Antineoplastic Agents
- Granulocyte Colony-Stimulating Factor
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.